DORA - Division of Insurance
Colorado Prescription Drug Affordability Review Board & Advisory Council
Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175 and updated under House Bill 23-1225, is a Type-1 Board within the Division of Insurance that has the authority to review prescription drug costs and evaluate their impact on Coloradans through affordability reviews of prescription drugs. The Board may then recommend ways to address those costs and may set an upper payment limit for certain prescription drugs.
Rulemaking Announcement
The Board will hold its first rulemaking hearing for Cosentyx UPL during the June 26, 2026 PDAB meeting. More information on the rulemaking can be found under the "PDAB Rulemaking" section.
Open PDAB Position
We are currently accepting applications from individuals who are interested in serving a term on the PDAB.
- Individuals must have an advanced degree and experience or expertise in health care economics or clinical medicine, per statute.
- Board members are appointed by the Governor and subject to confirmation by the Colorado Senate.
Individuals who meet the requirements may apply through the Colorado Boards and Commissions website.
Linked here is a one-page overview with additional details about the Board position and responsibilities.
Open PDAAC Position
We are currently accepting applications for the following positions on the Advisory Council:
- Individuals representing a labor union
- Individuals representing carriers
If you are interested in serving a 3-year term on the PDAAC, please fill out the linked application.
Listserv
To receive PDAB and PDAAC updates directly in your inbox, click here. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.
For questions, comments, or accessibility issues, email DOI staff at dora_ins_pdab@state.co.us.
Public Comment
To provide verbal comments to the PDAB, please sign up using this link. To provide verbal comments to the PDAAC, please sign up using this link. Or email dora_ins_pdab@state.co.us. Comments will be limited to 2 minutes per person.
To provide written comments to the PDAB/PDAAC, please email dora_ins_pdab@state.co.us up to 48 hours before each meeting. Comments submitted after the 48-hour deadline will be considered for the following meeting.
Testimony
Verbal or written testimony occurs only during PDAB rulemaking hearings and will be included in the rulemaking record. The Board may ask questions of stakeholders during their testimony. Visit the PDAB Rulemaking Guide for more information on testifying at a PDAB rulemaking hearing.
To provide verbal testimony to the PDAB, please fill out the testimony sign up form. Verbal testimony may be limited in duration.
To provide written testimony to the PDAB, please email dora_ins_pdab@state.co.us. Written testimonies will be accepted up to 48 hours before each rulemaking hearing. Testimonies submitted after the 48-hour deadline will be considered for the following rulemaking hearing.
- PDAB Members
- Dr. Sami Diab, MD
- Dr. Amy Gutierrez, PharmD - Interim Chair
- Catherine Harshbarger, RN, MHA
- Dr. James Justin VandenBerg, PharmD, BCPS
- Board Member - Vacant
- PDAAC Members
- Kim Bimestefer, Executive Director of HCPF
- Gail DeVore, representing health care consumers
- Roger Kelley, representing health care consumers
- Dr. Bob Mulch, representing statewide health care advocacy organizations
- PDAAC Chair, Dr. Kimberley Jackson, representing health care consumers living with chronic conditions
- Open position representing labor unions
- PDAAC Vice Chair, Nathan Wilkes, representing employers
- Open position representing carriers
- Marc Reece, representing PBMs
- Dr. Richard Miranda, representing health care professionals with prescribing authority
- Dr. Brett McQueen, representing research organizations
- Katelin Lucariello, representing brand name manufacturers
- Fayez Azeez, representing generic manufacturers
- Dr. Ingrid Pan, representing pharmacists
- Leah Lindahl, representing wholesalers
- Conflicts of Interest
PDAB Conflict of Interest Policy and Procedure
PDAB Conflict of Interest Disclosure
PDAB Meetings
The next PDAB meeting will be held virtually on Friday, June 26, 2026 from 10 am - 1 pm MT.
Register for June 26 PDAB Meeting
The link above is for a recurring webinar registration for the 2026 PDAB meetings. Only one registration is required for the meetings.
Click here to access 2026 PDAB and PDAAC meeting links and recordings.
June 26 Meeting Materials
- To provide verbal comments at the meeting, sign up here.
- Meeting agenda: coming soon.
- Meeting slides: coming soon.
- May 15 meeting minutes: coming soon.
- Draft CO PDAB 2025 Activities Summary Report
Materials related to the Cosentyx UPL rulemaking hearing can be found under the "PDAB Rulemaking" section.
Note: Previous meeting materials can be found under the "Public Resources" tab. Any materials not displayed on this website can be accessed by emailing dora_ins_pdab@state.co.us.
PDAAC Meetings
The next PDAAC meeting will be held virtually on Thursday, June 4, 2026 from 9 - 11 am MT.
Register for June 4 PDAAC Meeting
The link above is for a recurring webinar registration for the 2026 PDAAC meetings. Only one registration is required for the meetings.
June 4 Meeting Materials
- Meeting Agenda: coming soon.
- March 5 Meeting Minutes: coming soon.
- Written Comments: coming soon.
PDAB Rulemaking
The UPL rulemaking for Cosentyx will begin during the June 26, 2026 PDAB meeting. The Board anticipates holding at least 3 rulemaking hearings for the drug.
For more information on PDAB rulemaking and how to provide testimony during a rulemaking hearing, please visit the linked UPL Rulemaking Guide. Following are the documents related to Cosentyx's UPL rulemaking hearing:
- PDAB Rules and Policies
- Previous PDAB & PDAAC Meeting Materials
Note: meeting materials not displayed on this website can be accessed by emailing dora_ins_pdab@state.co.us.
- 2025 Upper Payment Limit Activities
The UPL rulemaking hearing for Enbrel began during the May 23, 2025 PDAB meeting. During the fourth hearing on October 3, 2025, the Board adopted the UPL rule for Enbrel and concluded the rulemaking hearing. The adopted rule can be found below.
Adopted UPL Rule for Enbrel (Etanercept)
Additional materials related to Enbrel's UPL rulemaking hearing can be found below:
- Written Testimonies
- Verbal Testimony Sign Up (currently inactive)
- Draft Proposed UPL Rule for Enbrel
- Data Submission Guide
- Confidential Information Submission Process
- UPL Benchmark Data Staff Memo
- Enbrel and Therapeutic Alternatives Benchmark Data
- Enbrel UPL Graph Packet
- Enbrel and Therapeutic Alternatives Price Data Methodology
- UPL Cost-Benefit Analysis & Regulatory Analysis
- Activities Summary Reports
- 2023/2024 Affordability Review Activities